Evidence map›Paper›PMID 40501679›Full record

ArticlebioRxiv : the preprint server for biology2025

Clonal Expansion of Alveolar Fibroblast Progeny Drives Pulmonary Fibrosis.

Christopher Molina, Tatsuya Tsukui, Imran Khan, Xin Ren, Wenli Qiu, Michael Matthay, Paul Wolters, Dean Sheppard

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Christopher MolinaDivision of Pulmonary and Critical Care Medicine, University of California San Francisco.
Tatsuya TsukuiDivision of Pulmonary and Critical Care Medicine, University of California San Francisco.
Imran KhanDivision of Neonatology, University of California San Francisco.
Xin RenDivision of Pulmonary and Critical Care Medicine, University of California San Francisco.
Wenli QiuDivision of Pulmonary and Critical Care Medicine, University of California San Francisco.
Michael MatthayDivision of Pulmonary and Critical Care Medicine, University of California San Francisco.
Paul WoltersDivision of Pulmonary and Critical Care Medicine, University of California San Francisco.
Dean SheppardDivision of Pulmonary and Critical Care Medicine, University of California San Francisco.

Funding

Fibroblast heterogeneity in pulmonary fibrosisR01HL142568 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHEPPARD, DEAN · 2020 to 2023
$2.9M
NHLBI NIH HHS R01 HL142568
6 · The paper itself

Abstract

Pulmonary fibrosis has been called a fibroproliferative disease but the functional importance of proliferating fibroblasts to pulmonary fibrosis has not been systematically examined. In response to alveolar injury, resting alveolar fibroblasts differentiate into fibrotic fibroblasts that express high levels of collagens. However, what role, if any, proliferation plays in the accumulation of fibrotic fibroblasts remains unclear. Through EdU incorporation, genetic lineage tracing, and single cell RNA sequencing, we resolve the proliferation dynamics of lung fibroblasts during post-injury fibrogenesis. Our data show substantial DNA replication in progeny of alveolar fibroblasts in two models of pulmonary fibrosis. By genetically labeling individual cells, we observe clonal expansion of alveolar fibroblast descendants principally in regions of fibrotic remodeling. The transcriptome of proliferating fibroblasts closely resembles that of fibrotic fibroblasts, suggesting that fibroblasts can first differentiate into fibrotic fibroblasts and then proliferate. Genetic ablation of proliferating fibroblasts and selective inhibition of cytokinesis in alveolar fibroblast descendants significantly mitigates pulmonary fibrosis and rescues lung function. Furthermore, fibroblasts in precision-cut lung slices from human fibrotic lungs exhibit higher proliferation rates than those in non-diseased lungs. This work establishes fibroblast proliferation as a critical driver of pulmonary fibrosis and suggests that specifically targeting fibroblast proliferation could be a new therapeutic strategy for fibrotic diseases.

Identifiers

PMID40501679
PMCPMC12157570

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.